TriSalus Life Sciences, Inc. (TLSI)
3.53
-0.10
(-2.75%)
USD |
NASDAQ |
Oct 19, 16:00
3.53
0.00 (0.00%)
After-Hours: 16:48
TriSalus Life Sciences Net Income (Quarterly) : -9.187M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.187M |
| March 31, 2026 | 1.539M |
| December 31, 2025 | -9.753M |
| September 30, 2025 | -10.81M |
| June 30, 2025 | -8.288M |
| March 31, 2025 | -10.38M |
| December 31, 2024 | -10.11M |
| September 30, 2024 | -2.399M |
| June 30, 2024 | -4.332M |
| March 31, 2024 | -13.21M |
| December 31, 2023 | -35.64M |
| September 30, 2023 | -1.425M |
| Date | Value |
|---|---|
| June 30, 2023 | -13.97M |
| March 31, 2023 | -8.268M |
| December 31, 2022 | -22.54M |
| September 30, 2022 | -8.093M |
| June 30, 2022 | 2.386M |
| March 31, 2022 | 2.837M |
| December 31, 2021 | 2.896M |
| September 30, 2021 | 1.865M |
| June 30, 2021 | 0.3789M |
| March 31, 2021 | -0.372M |
| September 30, 2020 | -0.001M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 11.41M |
| Total Expenses (Quarterly) | 20.59M |
| EPS Diluted (Quarterly) | -0.1576 |
| Enterprise Value | 211.27M |
| Gross Profit Margin (Quarterly) | 86.78% |
| Profit Margin (Quarterly) | -80.54% |
| Earnings Yield | -36.69% |
| Normalized Earnings Yield | -39.14 |